Finding your nearest Hydrotherapy Pool

Swimming is a low-impact form of exercise suitable for people with SMA, as it supports peoples body weight and reduces the strain on weakened muscles and joints. This low-impact nature allows individuals with SMA to improve their overall strength and endurance without the risk of injury.

Water buoyancy also helps improve muscle control, balance, and coordination. The water resistance serves as a natural form of resistance training, allowing for a gentle and gradual increase in muscle strength. Additionally, swimming can help maintain or improve range of motion and flexibility, which is crucial for those with SMA.

For all of these reasons, finding a local hydrotherapy swimming pool is important. to find your local, head on over to swimming.org and pop in your postcode.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more